Cargando…

Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study

BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kushner, Pamela, Peach, Emily, Wittbrodt, Eric, Barone, Salvatore, Chen, Hungta, Sanchez, Juan Jose Garcia, Järbrink, Krister, Arnold, Matthew, Tangri, Navdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967537/
https://www.ncbi.nlm.nih.gov/pubmed/35371463
http://dx.doi.org/10.1093/ckj/sfab235
_version_ 1784678862735540224
author Kushner, Pamela
Peach, Emily
Wittbrodt, Eric
Barone, Salvatore
Chen, Hungta
Sanchez, Juan Jose Garcia
Järbrink, Krister
Arnold, Matthew
Tangri, Navdeep
author_facet Kushner, Pamela
Peach, Emily
Wittbrodt, Eric
Barone, Salvatore
Chen, Hungta
Sanchez, Juan Jose Garcia
Järbrink, Krister
Arnold, Matthew
Tangri, Navdeep
author_sort Kushner, Pamela
collection PubMed
description BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and observational study aiming to provide insights into undiagnosed stage 3 CKD in a large population. METHODS: Patients (aged ≥18 years) with data in selected secondary databases from 11 countries will be included if they have at least two estimated glomerular filtration rate (eGFR) measurements from 2015 onwards that are ≥30 and <60 mL/min/1.73 m(2), recorded >90 and ≤730 days apart. Undiagnosed cases are those without an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before and up to 6 months after the second qualifying eGFR measurement. Time to diagnosis will be assessed using a Kaplan–Meier approach; patient characteristics associated with undiagnosed CKD will be assessed using adjusted logistical regression analyses. RESULTS: REVEAL-CKD will assess the point prevalence of undiagnosed stage 3 CKD and time to CKD diagnosis in initially undiagnosed cases overall and in individual countries. Trends in undiagnosed CKD prevalence by calendar year will be assessed. Patient characteristics, healthcare resource utilization, adverse clinical outcomes, and CKD management and monitoring practices in patients with versus without a CKD diagnosis will be compared. CONCLUSIONS: REVEAL-CKD will increase awareness of the global clinical and economic burden of undiagnosed stage 3 CKD and provide valuable insights to inform clinical practice and policy changes.
format Online
Article
Text
id pubmed-8967537
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89675372022-03-31 Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study Kushner, Pamela Peach, Emily Wittbrodt, Eric Barone, Salvatore Chen, Hungta Sanchez, Juan Jose Garcia Järbrink, Krister Arnold, Matthew Tangri, Navdeep Clin Kidney J Original Article BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and observational study aiming to provide insights into undiagnosed stage 3 CKD in a large population. METHODS: Patients (aged ≥18 years) with data in selected secondary databases from 11 countries will be included if they have at least two estimated glomerular filtration rate (eGFR) measurements from 2015 onwards that are ≥30 and <60 mL/min/1.73 m(2), recorded >90 and ≤730 days apart. Undiagnosed cases are those without an International Classification of Diseases 9/10 diagnosis code for CKD (any stage) any time before and up to 6 months after the second qualifying eGFR measurement. Time to diagnosis will be assessed using a Kaplan–Meier approach; patient characteristics associated with undiagnosed CKD will be assessed using adjusted logistical regression analyses. RESULTS: REVEAL-CKD will assess the point prevalence of undiagnosed stage 3 CKD and time to CKD diagnosis in initially undiagnosed cases overall and in individual countries. Trends in undiagnosed CKD prevalence by calendar year will be assessed. Patient characteristics, healthcare resource utilization, adverse clinical outcomes, and CKD management and monitoring practices in patients with versus without a CKD diagnosis will be compared. CONCLUSIONS: REVEAL-CKD will increase awareness of the global clinical and economic burden of undiagnosed stage 3 CKD and provide valuable insights to inform clinical practice and policy changes. Oxford University Press 2021-12-16 /pmc/articles/PMC8967537/ /pubmed/35371463 http://dx.doi.org/10.1093/ckj/sfab235 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Kushner, Pamela
Peach, Emily
Wittbrodt, Eric
Barone, Salvatore
Chen, Hungta
Sanchez, Juan Jose Garcia
Järbrink, Krister
Arnold, Matthew
Tangri, Navdeep
Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
title Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
title_full Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
title_fullStr Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
title_full_unstemmed Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
title_short Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
title_sort investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the reveal-ckd study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967537/
https://www.ncbi.nlm.nih.gov/pubmed/35371463
http://dx.doi.org/10.1093/ckj/sfab235
work_keys_str_mv AT kushnerpamela investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT peachemily investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT wittbrodteric investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT baronesalvatore investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT chenhungta investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT sanchezjuanjosegarcia investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT jarbrinkkrister investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT arnoldmatthew investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy
AT tangrinavdeep investigatingtheglobalprevalenceandconsequencesofundiagnosedstage3chronickidneydiseasemethodsandrationalefortherevealckdstudy